Drugs / Autologous MSCs
Autologous MSCs
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03298399 | Dec 2017 → Oct 2018 | sickle cell disease | Emory University | Withdrawn | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06103396 | Jan 2018 → Jan 2022 | disease of bone structure | Venezuelan Institute for Scientific Research | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05086939 | May 2021 → May 2025 overdue | osteoarthritis, knee | Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous MSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06103396 ↗ |
| Known as | BM-MSC | “The goal of this study is to evaluate the bone regeneration capacity of BM-MSC (Bone marrow mesenchymal stromal cells), in patients with nonunion.” NCT06103396 ↗ |
| Known as | EPIC2016-MSC003 | “This is a single center, phase I, open label dose escalation study designed to determine the safety and tolerability of autologous, bone marrow-derived MSCs (EPIC2016-MSC003)...” NCT03298399 ↗ |
| Known as | MSCs | “Autologuos MSCs harvested and cultured in osteogenic medium are seeded on collagen scaffold, and mixed with autologous rich plasma clot.” NCT06103396 ↗ |
| Modality | Cell therapy | “autologous, bone marrow-derived MSCs (EPIC2016-MSC003)” NCT03298399 ↗ |
| Route | Intravenous | “via intravenous infusion” NCT03298399 ↗ |